Chembio Diagnostics gains CLIA waiver
This article was originally published in The Gray Sheet
Executive Summary
Firm's HIV 1/2 Stat-Pak rapid HIV test gains waiver under the Clinical Laboratory Improvement Ammendments, allowing broad-scale marketing to 189,000 U.S. physician offices and clinics. Chembio expects U.S. marketing partner Inverness Medical to launch the test in early 2007, pending FDA sign-off on labeling changes. The test was approved by FDA in May along with Chembio's Sure Check HIV 1/2 rapid test, which still awaits CLIA waiver. Orasure (OraQuick Advance) and Trinity (Uni-Gold Recombigen) currently market the only CLIA-waived rapid HIV tests. Separately, Chembio is developing a rapid syphilis test using its Dual Path Platform (DPP) technology and syphilis antigens provided by the Centers for Disease Control & Prevention under a cooperative research and development agreement announced Nov. 27. Chembio also is using the DPP technology to develop an oral fluid HIV test (1"The Gray Sheet" Oct. 9, 2006, p. 16)...
You may also be interested in...
Chembio Clears Path For HIV Tests With Patent, Marketing Agreement
Chembio settled its legal disputes and found a marketing partner for its recently approved rapid HIV tests in a three-party agreement announced Oct. 5
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.